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PTEN is a frequently mutated tumor suppressor in
malignancies. Interestingly, some malignancies exhibit
undetectable PTEN protein without mutations or loss of
PTEN mRNA. The cause(s) for this reduction in PTEN is
unknown. Cancer cells frequently exhibit loss of cad-
herin, -catenin, -catenin and/or vinculin, key ele-
ments of adherens junctions. Here we show that F9 vin-
culin-null (vin/) cells lack PTEN protein despite
normal PTEN mRNA levels. Their PTEN protein expres-
sion was restored by transfection with vinculin or by
inhibition of PTEN degradation. F9 vin/ cells express
PTEN protein upon transfection with a vinculin frag-
ment (amino acids 243–1066) that is capable of interact-
ing with -catenin but unable to target into focal adhe-
sions. On the other hand, disruption of adherens
junctions with an E-cadherin blocking antibody re-
duced PTEN protein to undetectable levels in wild-type
F9 cells. PTEN protein levels were restored in F9 vin/
cells upon transfection with an E-cadherin--catenin fu-
sion protein, which targets into adherens junctions and
interacts with -catenin in F9 vin/ cells. -Catenin is
known to interact with MAGI-2. MAGI-2 interaction
with PTEN in the cell membrane is known to prevent
PTEN protein degradation. Thus, MAGI-2 overexpres-
sion in F9 vin/ cells restored PTEN protein levels.
Moreover, expression of vinculin mutants that rein-
stated the disrupted interactions of -catenin with
MAGI-2 in F9 vin/ cells also restored PTEN protein
levels. These studies indicate that PTEN protein levels
are dependent on the maintenance of -catenin-MAGI-2
interaction, in which vinculin plays a critical role.
Phosphatase and tensin homologue deleted on chromosome
10 (PTEN)1 is a lipid phosphatase that acts as a tumor sup-
pressor by negatively controlling the phosphoinositide 3-ki-
nase/Akt signaling pathway (1). PTEN belongs to a class of
“gatekeeper” tumor suppressors together with p53, retinoblas-
toma, and adenomatous polyposis coli (1). These proteins are
involved in the regulation of normal cell growth, and their
mutations contribute directly to carcinogenesis (1). PTEN is
one of the most frequently mutated proteins in cancer, but
reduction in PTEN protein levels cannot be attributed only to
observed mutations (2, 3). In cases of prostatic carcinoma,
leukemia, and lymphoma, PTEN protein levels are severely
reduced without detectable PTEN mutations or altered PTEN
mRNA expression (2, 3). The cause of the reduced PTEN protein
expression in these malignancies remains largely unknown.
A prevalent feature in various malignancies is decreased
expression of adherens junctions proteins, including E-cad-
herin, -catenin, -catenin, and/or vinculin (4–6). Adherens
junctions are multiprotein complexes with one of the highest
cellular concentrations of signaling proteins (7). Among these
signaling proteins are members of the membrane-associated
guanylate kinase family (8, 9). These scaffold proteins play a
critical role in signal transduction by optimizing the functional
activity and stability of their ligands (10, 11). PTEN interaction
with members of the membrane-associated guanylate kinase
family, such as membrane-associated guanylate-kinase in-
verted 2 (MAGI-2), prevents PTEN degradation (12, 13).
MAGI-2, also known as synaptic scaffolding molecule (14), has
been shown to interact with -catenin (15), a key element of the
adherens junction (16, 17). -Catenin is involved in the adhe-
rens junction assembly through its interaction with -catenin
and with cadherin. -Catenin directly links the Cadherin--
catenin complex to the cytoskeleton. The interactions of -cate-
nin with various cytoskeletal proteins are indispensable for
adherens junction assembly and function (16–18). Among
these cytoskeletal proteins is vinculin (16–18). In this study,
we found that cells devoid of vinculin have severely reduced
PTEN levels despite having normal levels of PTEN mRNA.
This was due to a disruption in the interaction of -catenin
with MAGI-2. This study reveals a novel mechanism of PTEN
regulation whereby its protein level is controlled through the
maintenance of -catenin-MAGI-2 interaction, with the ubiq-
uitous cytoskeletal protein vinculin playing a central role.
EXPERIMENTAL PROCEDURES
Cell Culture—The following cell lines were used: wild-type (WT) F9
cells; F9 vin/ cells; and F9 vin/ cells stably transfected with plas-
mid vectors expressing full-length vinculin (F9 vin/ rescue), a frag-
ment containing the sequences of the head portion of vinculin (F9 vin/
head; amino acids 1–821); and cells expressing the vinculin fragment
243–1066 in which the talin binding sites were deleted (F9 vin/ 
talin BS) (19). Cells were cultured as reported previously (19).
Reverse Transcription-PCR—Total RNA was isolated from both WT
F9 and F9 vin/ cells (3  106 cells) using RNeasy Mini Kit from
Qiagen according to the manufacturer’s instructions. First-strand
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FIG. 1. PTEN is restored to WT level and activity in F9 vin/ cells
transfected with vinculin. A, detergent lysates of WT F9 cells, F9 vin/,
and F9 vin/ rescue cells were analyzed by immunoblotting using anti-
PTEN and anti-ERK1/2 Ab. The result shown is a representative example
from 10 experiments. B, cell lysates of WT F9, F9 vin/, and F9 vin/
rescue cells were analyzed by immunoblotting using anti-Akt and anti-
phospho-Akt Ab. Results of one representative experiment of five are shown.
FIG. 2. PTEN mRNA levels are the same in WT F9 cells and F9
vin/ cells, and PTEN levels are restored in F9 vin/ cells upon
proteasome inhibition. A, levels of PTEN and -actin mRNA in WT
F9 and F9 vin/ cells were assessed by reverse transcription-PCR.
Aliquots drawn at the indicated cycles were visualized on an agarose
gel. WT F9 cells, lanes 1, 3, 5, and 7. F9 vin / cells, lanes 2, 4, 6, and
8. Representative results from one of two experiments are shown. B,
detergent lysates from WT F9, F9 vin/, and F9 vin/ cells treated for
36 h with lactacystin (8 nM) were analyzed by immunoblotting using
anti-PTEN and anti-ERK Ab. The result shown is a representative
example from three experiments. C, cell lysates from WT F9, F9 vin/,
and F9 vin/ cells treated for 36 h with lactacystin (8 nM) were
analyzed by immunoblotting using anti-Akt and anti-phospho-Akt Ab.
Results of one representative experiment of three are shown.
FIG. 3. PTEN expression and activity in F9 vin/ cells trans-
fected with various vinculin constructs. A, vinculin mutants. Top
line, full-length vinculin. Second line, the head fragment (amino acids
1–821). Third line, the vinculin fragment in which talin binding sites
were deleted (amino acids 243–1066). B, cell lysates from F9 vin/ 
talin bs cells were immunoprecipitated with an anti--catenin antibody,
followed by immunoblotting with an antibody against vinculin. Repre-
sentative results from one of two experiments are shown. C, detergent
lysates of these cell lines were analyzed by immunoblotting using anti-
PTEN and anti-ERK1/2 Ab. Results from one representative experi-
ment of three are shown. D, cell lysates of WT F9, F9 vin/, F9 vin/
talin bs, and F9 vin/ head cells were analyzed by immunoblotting
using anti-Akt and anti-phospho-Akt Ab. Representative results from
one of three independent experiments are shown.
FIG. 4. Disruption of adherens junction with a function-per-
turbing anti-E-cadherin antibody, DECMA-1, reduces PTEN
protein expression in WT F9, F9 vin/  talin bs, and F9 vin/
head cells. Detergent lysates of WT F9, F9 vin/, F9 vin/  talin bs,
and F9 vin/ head cells treated with or without the neutralizing
antibody against E-cadherin (DECMA-1) were analyzed by immuno-
blotting using anti-PTEN and anti-ERK1/2 Ab. Results from one rep-
resentative experiment of three are shown.
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cDNA was reverse-transcribed from 1 g of total RNA using avian
myeloblastosis virus reverse transcriptase (Promega) with oligo(dT)15
as primer. The reaction volume was 20 l, of which 5 l were used to
amplify a fragment of the -actin gene for semiquantitative analysis of
the amount of total RNA added to the PCRs. Amplification of the 285-bp
PTEN fragment was performed with 10 l of the reverse transcription
reaction. Oligonucleotide primers for the PCR amplification were based
on the published PTEN sequence (GenBankTM accession no. U93051)
and -actin sequence (GenBankTM accession no. X00351), respectively.
The primer sequences are as follows: PTENf, GATTTCTATGGGGAA-
GTAAGGA; PTENrev, GTAACGGCTGAGGGAACTC; actinf, GATAT-
CGCCGCGCTCGTCGTCGAC; and actinrev, CAGGAAGGAAGGCTG-
GAAGAGTGC. PCRs were performed in a 50-l volume containing 10
mM Tris (pH 8.4), 50 mM KCl, 1 mM MgCl2, oligonucleotide primers (0.1
M of each), 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dGTP, 0.2 mM dCTP,
and 2.5 units of Taq DNA polymerase. PCR cycles were as follows: 94 °C
for 2 min; followed by 30–36 cycles of 94 °C for 30 s, 55 °C for 30 s, and
72 °C for 1 min; and a final cycle of 72 °C for 5 min. Samples (6 l) were
drawn from the PCR at the indicated cycles to be visualized on an
agarose gel.
Preparation of Protein Extracts, Immunoblotting, and Immunopre-
cipitation—For immunoblotting analyses, cells were lysed in a buffer
containing 20 mM Tris-HCl (pH 8), 100 mM NaCl, 10% glycerol, 1%
Triton X-100, 50 mM NaF, 1 mM sodium vanadate, 1 mM benzamidine,
5 g ml1 leupeptin, and 1 mM phenylmethylsulfonyl fluoride. The cell
lysates were clarified at 10,000  g for 10 min at 4 °C. Samples were
separated on SDS-polyacrylamide gels (Bio-Rad). Proteins were trans-
ferred to Immobilon-P transfer membranes (Millipore Corp.) blocked
and probed with the following antibodies (Abs): rabbit anti-ERK1/2 Ab,
rabbit anti-Akt Ab, rabbit anti-phospho-Akt Ab, and rabbit anti-PTEN
Ab (all from Cell Signaling Technology); rabbit anti--catenin Ab
(Chemicon Corp.); mouse monoclonal anti-E-cadherin Ab and mouse
monoclonal anti- -catenin Ab (both from BD Biosciences); rabbit anti-
MAGI-2 (Santa Cruz Biotechnology). Bound antibody was detected by
incubation with secondary antibodies conjugated with horseradish per-
oxidase (rabbit and mouse horseradish peroxidase-derived Ab were
from Cell Signaling, and rabbit horseradish peroxidase-derived Ab was
from Santa Cruz Biotechnology) and visualized by enhanced chemilu-
minescence (Pierce). Equal loading in each lane was verified by assess-
ing ERK1/2 concentration.
Immunoprecipitation studies were carried out according to a method
reported previously (17), with some minor modifications, using the
mouse anti--catenin Ab, rabbit anti--catenin Ab, and rabbit anti-
MAGI-2 Ab mentioned in the immunoblotting studies, as well as a
mouse anti-PTEN Ab (Santa Cruz Biotechnology) and a mouse anti-
paxillin Ab (BD Biosciences) at a concentration of 1:300.
Plasmids and Transfection—E-cadherin--catenin construct (18)
was kindly provided by Dr. Akira Nagafuchi, and pcDNA3 MAGI-2-
myc-tagged protein (11) was a gift from Dr. Charles Sawyers. Transient
transfections were done using Lipofectamine and Plus Reagent (Invitro-
gen) following the manufacturer’s instructions. In brief, F9 cell lines
were transfected with 8 l of Lipofectamine, 16 l of Plus Reagent, and
7 g of the plasmids. Cells were used 48 h after transfection. The
protein expression of MAGI-2-myc-tagged protein and E-cadherin--
catenin (E-cad--cat) was confirmed by immunoblotting with a mouse
anti-myc Ab (Sigma) and a mouse anti-E-cadherin Ab (BD Biosciences),
respectively.
Cadherin Blocking Experiments—Neutralizing antibody against
E-cadherin (DECMA-1 Ab; Accurate Chemical & Scientific Corp.) was
mixed at a concentration of 30 g ml1 with confluent cells in -min-
imum Eagle’s medium containing 10% fetal bovine serum (Invitro-
gen). After 18 h, cells were lysed, and PTEN protein levels were
assessed by immunoblotting.
RESULTS
PTEN Protein Expression Is Undetectable in F9 vin/ Cells
and Is Restored upon Proteasome Inhibition—Mouse F9 vin/
embryonal carcinoma cells had undetectable PTEN protein
levels (Fig. 1A). F9 vin/ cells re-expressing vinculin to WT
levels (F9 vin/ rescue cells) (19, 20) exhibit a restoration of
PTEN expression to the levels seen in WT F9 cells. The resto-
ration of PTEN activity in F9 vin/ rescue cells was reflected
in reduction of the increased Akt phosphorylation seen in F9
vin/ cells (Fig. 1B). Thus, vinculin is involved in the regula-
tion of PTEN protein expression.
PTEN protein levels can be controlled by different mecha-
nisms (3). In this regard, PTEN protein levels can be regu-
lated at the transcriptional level by transcription factors such
as p53 or Egr-1 (21, 22). As seen in Fig. 2A, PTEN mRNA
FIG. 5. Transfection of E-cadherin-
-catenin fusion protein or MAGI-2
leads to PTEN expression in F9 vin/
cells. A, cell lysates from F9 vin/ cells
transfected with an E-cadherin--catenin
(E-cad--cat) fusion protein were immu-
noprecipitated with an anti--catenin an-
tibody, followed by immunoblotting with
an antibody against E-cadherin. Repre-
sentative results from one of two experi-
ments are shown. Cell lysates from F9
vin/ cells transfected with E-cadherin-
-catenin protein were analyzed by im-
munoblotting using anti-PTEN and anti-
ERK1/2 Ab (B) and anti-E-cadherin Ab
(C). The results shown in B and C are
representative examples from three inde-
pendent experiments. D, detergent ly-
sates of F9 vin/ cells transfected with
MAGI-2-myc-tagged protein were ana-
lyzed by immunoblotting using anti-
PTEN and anti-ERK1/2 Ab. Results from
one of two experiments are shown.
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levels were similar in F9 vin/ cells and WT F9 cells, so
decreased PTEN in F9 vin/ cells could not be explained by
loss of mRNA expression. PTEN protein levels can also be
regulated by a proteasome-mediated proteolytic degradation
(13, 23). As seen in Fig. 2B, treatment with lactacystin
(Sigma), a potent proteasome inhibitor, led to restoration of
PTEN expression in F9 vin/ cells. Lactacystin treatment
also led to a reduction of the increased Akt phosphorylation
seen in F9 vin/ cells (Fig. 2C). These data indicated that
vinculin regulates PTEN protein stability by affecting its
proteasome-mediated proteolytic degradation.
PTEN Levels Are Restored in F9 vin/ Cells Transfected
with Vinculin Constructs That Interact with -Catenin,
Whereas Disruption of Adherens Junctions Reduces PTEN Ex-
pression in Wild-type Cells—Vinculin is a major cytoskeletal
protein present in focal adhesions and adherens junctions (24).
In order to address how vinculin controls PTEN protein expres-
sion, F9 vin/ cells were stably transfected with a vinculin
head fragment (F9 vin/ head cells) or a vinculin fragment
with the talin binding sites deleted (F9 vin/  talin bs cells)
(19) (Fig. 3A), and the PTEN protein levels in these cells were
compared with the levels seen in WT F9 cells and F9 vin/
cells. Vinculin head domain is known to target into focal adhe-
sions as well as adherens junctions (17). The vinculin  talin bs
fragment cannot target into focal adhesions (25) but can still
interact with -catenin, a protein present only in the adherens
junctions (Fig. 3B). As shown in Fig. 3, C and D, PTEN protein
level and activity were restored to wild-type levels in F9 vin/
cells expressing the vinculin head as well as  talin bs frag-
ments. On the other hand, incubation with DECMA-1 Ab, an
antibody known to block E-cadherin-mediated adherens junc-
tion formation (26), led to a loss of PTEN protein expression in
WT F9 cells as well as in F9 vin/ head and F9 vin/  talin
bs cells (Fig. 4). These data indicated that regulation of PTEN
protein level by vinculin is at the adherens junction.
Transfection of E-Cadherin--Catenin Fusion Protein or
MAGI-2 Restores PTEN Levels in F9 vin/ Cells—It has been
demonstrated previously that adherens junction organization
is impaired in F9 vin/ cells (16). Vinculin plays an important
role in adherens junction organization and function through its
interaction with the cytoskeleton (18). Therefore, PTEN pro-
tein levels were examined in F9 vin/ cells transfected with an
E-cadherin--catenin fusion protein because this protein pro-
duces cadherin-based cell adhesion activity even in the absence
of vinculin (18). This fusion protein includes the complete
-catenin protein; therefore, the -catenin binding site is pre-
served (27). In fact, we found that this fusion protein interacts
with -catenin in F9 vin/ cells (Fig. 5A). As shown in Fig. 5B,
expression of the E-cadherin--catenin fusion protein restored
PTEN levels in F9 vin/ cells. Restoration was not complete,
likely because the fusion protein was poorly expressed com-
pared with native E-cadherin (Fig. 5C).
The activity and stability of PTEN are dependent on its
interaction with the PSD-95/Discs-large/ZO-1 homology do-
mains of proteins belonging to the membrane-associated gua-
nylate kinase family, such as MAGI-2 or -3 (11, 13, 28). These
scaffold proteins are known to localize into adherens junction
and interact with -catenin (8, 15). Overexpression of MAGI-2
led to restoration of PTEN protein expression in F9 vin/ cells
(Fig. 5D).
Expression of Vinculin Mutants That Restored PTEN Protein
Levels Also Restored the Disrupted Interactions of -Catenin
with MAGI-2 in F9 vin/ Cells—Thus far, we have found that
the control of PTEN protein expression by vinculin is at the
level of the adherens junction (Figs. 3, 4, and 5B). Furthermore,
PTEN protein stability is restored upon overexpression of
MAGI-2 (Fig. 5D). This scaffold protein is known to bind to the
adherens junction protein -catenin. Because F9 vin/ cells
exhibit a disruption of adherens junction organization (16),
their loss of PTEN protein expression could be associated with
an impaired -catenin-MAGI-2 interaction. To gauge the level
of MAGI-2--catenin interaction in different cell lysates, either
MAGI-2 or -catenin was immunoprecipitated, and immuno-
blotting was used to probe for the presence of the binding
partner (Fig. 6, A and B). As shown in Fig. 6, A and B, inter-
FIG. 6. Decreased binding of -catenin MAGI-2 in F9 vin/
cells is restored to WT levels in F9 vin/ talin bs and F9 vin/
head cells. A, cell lysates from WT F9, F9 vin/, F9 vin/ talin bs,
and F9 vin/ head cells were immunoprecipitated with an anti--
catenin antibody, followed by immunoblotting with an antibody against
MAGI-2. Representative results from one of two independent experi-
ments are shown. B, cell lysates from WT F9, F9 vin/, F9 vin/
talin bs, and F9 vin/ head cells were immunoprecipitated with an
anti-MAGI-2 antibody, followed by immunoblotting with an antibody
against -catenin. Representative results from one of two independent
experiments are shown. C, detergent cell lysates from WT F9, F9
vin/, F9 vin/ talin bs, and F9 vin/ head cells were analyzed by
immunoblotting using anti--catenin, anti-MAGI-2, and anti-ERK Ab.
Representative results from one of three independent experiments are
shown.
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action of -catenin with MAGI-2 was decreased in F9 vin/
cells. MAGI-2--catenin interaction was restored to WT levels
in the PTEN-expressing F9 vin/  talin bs and F9 vin/
head cells (Fig. 6, A and B). There was no difference in -cate-
nin and MAGI-2 protein levels among WT F9, vin/, vin/
head, and vin/  talin bs cells (Fig. 6C). Therefore, vinculin
mutants that restored PTEN protein levels also restored the
disrupted MAGI-2--catenin interaction in F9 vin/ cells.
DISCUSSION
PTEN is a tumor suppressor involved in the control of fun-
damental biological processes including the cell cycle, apopto-
sis, and motility (29–33). Loss of PTEN is commonly found in
highly aggressive tumors (3). Multiple mechanisms leading to
altered PTEN protein levels, besides PTEN mutations, have
been entertained (3). In this regard, our results demonstrate
that tumor cells devoid of vinculin have undetectable PTEN
protein levels due to a disrupted interaction between -catenin
and MAGI-2.
Vinculin-null cells exhibit undetectable PTEN protein con-
centration despite their normal mRNA levels. Thus, regulation
of PTEN protein by vinculin is not at the transcriptional level.
In fact, our findings reveal that vinculin regulates PTEN pro-
tein levels by affecting ubiquitin-mediated proteolytic degrada-
tion of PTEN. Interestingly, inactivation of PTEN through
protein degradation is reminiscent of other tumor suppressors
such as p53 and p27Kip1, which have reduced stability in some
cancer cells (34, 35).
Our results demonstrate that the effect of vinculin on PTEN
protein expression was at the level of the adherens junction.
This was demonstrated through transfection of vinculin-null
cells with a vinculin mutant that could not localize into focal
adhesions (25) but could interact with -catenin. This mutant
was capable of restoring PTEN protein to wild-type levels.
Furthermore, expression of an E-cadherin--catenin fusion
protein restored PTEN protein expression. This fusion protein
is known to localize in adherens junctions and restore cad-
herin-based cell adhesion activity (18). Moreover, our studies
demonstrate that it can interact with -catenin in F9 vin/
cells. These findings are apparently in contradiction with pre-
vious studies, in which no interaction of this fusion protein
with -catenin was found. These differences could be due to the
fact that we used epithelial cells, whereas the previous study
used fibroblasts (18). It is known that the adherens junction
organization is different in these two cell types (18). -Catenin
has been shown to interact with MAGI-2, besides being in-
volved in adherens junction assembly (15). In this regard, we
found that MAGI-2 interaction with -catenin was disrupted in
vinculin-null cells. Interestingly, a previous study has found
that the localization of zonnula occludens-1, another member of
the membrane-associated guanylate kinase family, in the api-
cal junctional complex was disrupted in these cells and that its
targeting into these complexes was restored upon vinculin re-
expression (16). In our studies, the disrupted MAGI-2--cate-
nin interaction was restored in vinculin-null cells upon expres-
sion of vinculin mutants capable of interacting with -catenin.
MAGI-2 interaction with PTEN is known to prevent PTEN
degradation (12, 13). In our studies, overexpression of MAGI-2
in vinculin-null cells led to restoration of their PTEN protein
FIG. 7. Vinculin regulates PTEN
protein level by maintaining the in-
teraction of -catenin with MAGI-2.
A, cell lysates from WT F9 cells were im-
munoprecipitated with an anti-PTEN an-
tibody, followed by immunoblotting with
an antibody against MAGI-2 as well as
-catenin. Representative results from
one of two independent experiments are
shown. B, cell lysates from WT F9 cells
were immunoprecipitated with an anti-
paxillin antibody, followed by immuno-
blotting with an antibody against MAGI-2
as well as -catenin. Representative re-
sults from one of two independent exper-
iments are shown. C, model for the role of
vinculin in controlling PTEN protein ex-
pression and function by maintaining the
interaction of -catenin with MAGI-2.
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levels. Moreover, restoration of the disrupted MAGI-2--cate-
nin interaction in these cells was associated with re-expression
of PTEN protein.
Based on previous studies and our results, we propose a
model (Fig. 7C) in which -catenin present in the E-cadherin-
-catenin--catenin complex provides a link for MAGI-2 in the
adherens junction. PTEN will then be recruited through its
direct interaction with MAGI- 2 (11). Thus, a PTEN-MAGI-2-
-catenin heterotrimeric complex will be formed as reflected by
the specific capacity of anti-PTEN Ab (Fig. 7A), but not a
nonspecific (anti-paxillin) Ab (Fig. 7B), to co-immunoprecipi-
tate PTEN, MAGI-2, and -catenin (Fig. 7A). In E-cadherin
complexes, -catenin interacts directly with p85, the regulatory
subunit of phosphoinositide 3-kinase (36). Thus, in the pro-
posed complex, PTEN will inhibit the phosphoinositide 3-ki-
nase/Akt pathway by efficiently dephosphorylating phosphati-
dylinositol 3,4,5-triphosphate (1). The interaction of MAGI-2
with PTEN will also stabilize PTEN (11). Certain PTEN mu-
tants incapable of binding to MAGI-2 have reduced protein
stability (12), which is restored by adding back the minimal
PSD-95/Discs-large/ZO-1 homology-binding motif of PTEN
(12). The unstable PTEN protein is degraded through a ubiq-
uitin-associated proteolytic process (13, 23). By maintaining
MAGI-2--catenin interaction, vinculin could restrict ubiq-
uitin-mediated degradation of PTEN.
This study also suggests a mechanistic explanation for the
loss of PTEN in multiple cases of malignancies that do not
exhibit mutations or loss of PTEN mRNA expression (2, 3). A
common feature of these tumors is decreased expression of
E-cadherin, -catenin, or -catenin, key elements in adherens
junctions (5, 6). In this regard, disruption of adherens junction
formation with an E-cadherin blocking antibody led to loss of
PTEN protein expression in WT F9 cells. Future work could
address the prevalence of this mechanism as a cause for loss of
PTEN expression in malignancies. These findings could also be
relevant in the understanding of physiological processes be-
cause adherens junction organization is a highly dynamic proc-
ess. In this regard, adherens junction assembly has been im-
plicated in developmental morphogenesis (37). Interestingly,
very recent studies have also shown a role for PTEN in neuro-
nal development (38, 39). A minimal decrease in PTEN protein
levels in neuronal progenitors significantly enhances the activ-
ity of the Akt/phosphoinositide 3-kinase kinase pathway (40).
Thus, future work could be directed to addressing whether the
dynamic changes of adherens junction assembly play an impor-
tant role in neurite development by directly regulating PTEN
protein levels. In summary, this work has uncovered an impor-
tant mechanism of PTEN regulation, in which PTEN protein
levels and activity are controlled through the maintenance of
-catenin-MAGI-2 interaction.
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